Andy Pasternak compensation by year
Horizon Therapeutics Public Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $669,021 | $692,372 | $719,506 |
| Bonus | $250,000 | $0 | $503,752 |
| Stock awards | $4,037,409 | $5,272,731 | $5,355,203 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $802,825 | $814,368 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $66,872 | $167,855 | $174,333 |
| Total | $5,826,126 | $6,947,326 | $6,752,794 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Horizon Therapeutics Public Ltd Co DEF 14A filed June 30, 2023, accession 0001193125-23-180318, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Horizon Therapeutics Public Ltd Co filed document, accession 0001193125-23-180318. Every figure is read from that document and cited to the page and table it appears in. Filed June 30, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 50,001 | $5,690,114 | — |
| RSU | 33,329 | $3,792,840 | — |
| PSU | 26,196 | $2,981,105 | — |
| PSU | 23,805 | $2,709,009 | — |
| RSU | 15,870 | $1,806,006 | — |
| RSU | 11,643 | $1,324,973 | — |
| PSU | 5,816 | $661,861 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Horizon Therapeutics Public Ltd Co's FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
13 Form 4 lines since the FY2022 proxy (filed June 30, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-10-06 | Disposition to the issuer derivative | — | 5,749 | — | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 11,643 | — | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 5,816 | — | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 23,806 | — | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 11,499 | — | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 5,749 | — | 0 |
| 2023-10-06 | Disposition to the issuer | — | 56,338 | $116.50 | 0 |
| 2023-10-06 | Disposition to the issuer derivative | — | 15,870 | — | 0 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Horizon Therapeutics Public discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $724,148 | $0 | $26,276 | $750,424 |
| Change in control and involuntary termination | $1,086,222 | $9,482,954 | $39,414 | $11,368,945 |
Per the Potential Payments Upon Termination or Change in Control table in Horizon Therapeutics Public Ltd Co's FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
Horizon Therapeutics Public’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Timothy Walbert | Chairman, President and Chief Executive Officer | $20,103,869 |
| Sean Clayton | Executive Vice President, General Counsel | $10,872,207 |
| Elizabeth Thompson | Executive Vice President, Research and Development | $8,481,020 |
| Aaron Cox | Executive Vice President, Chief Financial Officer | $7,174,543 |
| Andy Pasternak · this page | Executive Vice President, Chief Strategy Officer | $6,752,794 |
| Paul Hoelscher | Former Executive Vice President, Chief Financial Officer | $1,822,581 |
The full Horizon Therapeutics Public compensation record
free company briefThis page is one person within Horizon Therapeutics Public's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Horizon Therapeutics Public proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Horizon Therapeutics Public's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.